

# Anti-Obesity Prescription Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/AB2D8E156C9EN.html>

Date: February 2018

Pages: 160

Price: US\$ 3,480.00 (Single User License)

ID: AB2D8E156C9EN

## Abstracts

### Report Summary

Anti-Obesity Prescription Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti-Obesity Prescription Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Anti-Obesity Prescription Drugs 2013-2017, and development forecast 2018-2023

Main market players of Anti-Obesity Prescription Drugs in EMEA, with company and product introduction, position in the Anti-Obesity Prescription Drugs market

Market status and development trend of Anti-Obesity Prescription Drugs by types and applications

Cost and profit status of Anti-Obesity Prescription Drugs, and marketing status

Market growth drivers and challenges

The report segments the EMEA Anti-Obesity Prescription Drugs market as:

EMEA Anti-Obesity Prescription Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Anti-Obesity Prescription Drugs Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Bupropion and Naltrexone  
Orlistat  
Lorcaserin  
Phentermine and Topiramate  
Liraglutide

EMEA Anti-Obesity Prescription Drugs Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and  
Market Analysis)

Hospitals Pharmacies  
Retail Pharmacies  
E-commerce

EMEA Anti-Obesity Prescription Drugs Market: Players Segment Analysis (Company  
and Product introduction, Anti-Obesity Prescription Drugs Sales Volume, Revenue,  
Price and Gross Margin):

VIVUS  
Orexigen Therapeutics  
Novo Nordisk  
F Hoffmann La Roche  
Arena Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF ANTI-OBESITY PRESCRIPTION DRUGS**

- 1.1 Definition of Anti-Obesity Prescription Drugs in This Report
- 1.2 Commercial Types of Anti-Obesity Prescription Drugs
  - 1.2.1 Bupropion and Naltrexone
  - 1.2.2 Orlistat
  - 1.2.3 Lorcaserin
  - 1.2.4 Phentermine and Topiramate
  - 1.2.5 Liraglutide
- 1.3 Downstream Application of Anti-Obesity Prescription Drugs
  - 1.3.1 Hospitals Pharmacies
  - 1.3.2 Retail Pharmacies
  - 1.3.3 E-commerce
- 1.4 Development History of Anti-Obesity Prescription Drugs
- 1.5 Market Status and Trend of Anti-Obesity Prescription Drugs 2013-2023
  - 1.5.1 EMEA Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023
  - 1.5.2 Regional Anti-Obesity Prescription Drugs Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Anti-Obesity Prescription Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Anti-Obesity Prescription Drugs in EMEA by Regions
  - 2.2.1 Consumption Volume of Anti-Obesity Prescription Drugs in EMEA by Regions
  - 2.2.2 Revenue of Anti-Obesity Prescription Drugs in EMEA by Regions
- 2.3 Market Analysis of Anti-Obesity Prescription Drugs in EMEA by Regions
  - 2.3.1 Market Analysis of Anti-Obesity Prescription Drugs in Europe 2013-2017
  - 2.3.2 Market Analysis of Anti-Obesity Prescription Drugs in Middle East 2013-2017
  - 2.3.3 Market Analysis of Anti-Obesity Prescription Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Anti-Obesity Prescription Drugs in EMEA 2018-2023
  - 2.4.1 Market Development Forecast of Anti-Obesity Prescription Drugs in EMEA 2018-2023
  - 2.4.2 Market Development Forecast of Anti-Obesity Prescription Drugs by Regions 2018-2023

### **CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole EMEA Market Status by Types
  - 3.1.1 Consumption Volume of Anti-Obesity Prescription Drugs in EMEA by Types
  - 3.1.2 Revenue of Anti-Obesity Prescription Drugs in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in Europe
  - 3.2.2 Market Status by Types in Middle East
  - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Anti-Obesity Prescription Drugs in EMEA by Types

## **CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Anti-Obesity Prescription Drugs in EMEA by Downstream Industry
- 4.2 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Europe
  - 4.2.2 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Middle East
  - 4.2.3 Demand Volume of Anti-Obesity Prescription Drugs by Downstream Industry in Africa
- 4.3 Market Forecast of Anti-Obesity Prescription Drugs in EMEA by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS**

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Anti-Obesity Prescription Drugs Downstream Industry Situation and Trend Overview

## **CHAPTER 6 ANTI-OBESITY PRESCRIPTION DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA**

- 6.1 Sales Volume of Anti-Obesity Prescription Drugs in EMEA by Major Players
- 6.2 Revenue of Anti-Obesity Prescription Drugs in EMEA by Major Players
- 6.3 Basic Information of Anti-Obesity Prescription Drugs by Major Players
  - 6.3.1 Headquarters Location and Established Time of Anti-Obesity Prescription Drugs Major Players

- 6.3.2 Employees and Revenue Level of Anti-Obesity Prescription Drugs Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 ANTI-OBESITY PRESCRIPTION DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

### **7.1 VIVUS**

- 7.1.1 Company profile
- 7.1.2 Representative Anti-Obesity Prescription Drugs Product
- 7.1.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of VIVUS

### **7.2 Orexigen Therapeutics**

- 7.2.1 Company profile
- 7.2.2 Representative Anti-Obesity Prescription Drugs Product
- 7.2.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics

### **7.3 Novo Nordisk**

- 7.3.1 Company profile
- 7.3.2 Representative Anti-Obesity Prescription Drugs Product
- 7.3.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk

### **7.4 F Hoffmann La Roche**

- 7.4.1 Company profile
- 7.4.2 Representative Anti-Obesity Prescription Drugs Product
- 7.4.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of F Hoffmann La Roche

### **7.5 Arena Pharmaceuticals**

- 7.5.1 Company profile
- 7.5.2 Representative Anti-Obesity Prescription Drugs Product
- 7.5.3 Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS**

### **8.1 Industry Chain of Anti-Obesity Prescription Drugs**

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS**

9.1 Cost Structure Analysis of Anti-Obesity Prescription Drugs

9.2 Raw Materials Cost Analysis of Anti-Obesity Prescription Drugs

9.3 Labor Cost Analysis of Anti-Obesity Prescription Drugs

9.4 Manufacturing Expenses Analysis of Anti-Obesity Prescription Drugs

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI-OBESITY PRESCRIPTION DRUGS**

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

## I would like to order

Product name: Anti-Obesity Prescription Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/AB2D8E156C9EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AB2D8E156C9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970